VANCOUVER, BC / ACCESSWIRE / May 28, 2019 / THERAMED HEALTH CORP. (CSE: TMED, OTCQB: EVAHF) (the “Company“) is pleased to have one of their scientific advisors co-hosting various panels in one of the leading international extraction and analytical testing conferences.
THERAMED’S Chief Science Advisor, Dr. Ricardo E Rivera-Acevedo will be a panelist at CONCENTRATION 2019, a first of its kind conference on all matters pertaining to extraction technology and analytical testing within the cannabis industry. “CONCENTRATION 2019 is a breakthrough event assembling the entire specialty cannabis extraction and analytical science spectrum in one smart, connected space that’s focused on providing real solutions with proven success.” The event is being held in California and is expected to attract over 2,500 attendees from throughout the cannabis and hemp industry. The speakers, exhibits, demo’s, and panels will cover a wide-range of topics on the industry’s cutting-edge.
“We are excited to have Dr. Rivera-Acevedo, one of our own advisors, at this dynamic event and showcase the level of knowledge in the cannabis industry that he has become known for.” Commented C.K. Cheung, CEO of Theramed.
The Company continues to work on developing new technologies and pharmacological formulations for a personalized CBD healthcare system; in order to better serve patients that could also benefit from medicinal cannabis-based therapies.
THERAMED HEALTH CORPORATION
Email [email protected]
CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news
About THERAMED HEALTH
(CSE: TMED, OTCQB: EVAHF)
Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.
This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/Theramed-Health-Corporation, and http://www.otcmarkets.com/stock/EVAHF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.
SOURCE: THERAMED HEALTH CORP.
View source version on accesswire.com: